• Ziprasidone Augmentation of Escitalopram in Anxious Depressi

  2026-05-20

  This study rigorously evaluated whether adding ziprasidone to escitalopram yields additional benefits for patients with anxious depression versus those without. The key finding is that ziprasidone augmentation did not confer clinically meaningful anxiolytic effects, underscoring the need for more targeted approaches in antidepressant research.

• Bestatin (Ubenimex): Precision Aminopeptidase Inhibition in

  2026-05-20

  Bestatin (Ubenimex) stands out as a highly specific aminopeptidase inhibitor, enabling reproducible assays in cancer and multidrug resistance research. Its unique solubility and selectivity profile unlock new experimental workflows, as evidenced by recent advances in angiogenesis modeling and apoptosis evaluation.

• Calpeptin: Mechanistic Insights and Strategic Impact in Fibr

  2026-05-19

  This article explores Calpeptin’s mechanistic role as a calpain inhibitor in modulating fibrosis and inflammation, synthesizing current evidence from translational models and recent studies on extracellular vesicle biology. It offers strategic guidance for researchers navigating complex disease modeling, protocol design, and the evolving competitive landscape, with a forward-looking perspective on translational opportunities and experimental rigor.

• Nonivamide (Capsaicin Analog): Translating TRPV1 Agonism to

  2026-05-19

  Discover how Nonivamide, a selective capsaicin analog, uniquely enables advanced TRPV1-driven studies in inflammation and cancer research. Explore mechanistic insights, translational assay guidance, and practical protocol parameters that set this article apart.

• M344: Next-Generation HDAC Inhibition in Neuroblastoma Resea

  2026-05-18

  Explore how M344, a potent histone deacetylase inhibitor, is reshaping neuroblastoma and pediatric cancer research through advanced epigenetic modulation. This article delivers a unique, evidence-driven perspective on assay design, clinical translation, and future directions.

• PINK1/Park2 Mitophagy Alleviates NAFLD: Mechanistic Insights

  2026-05-18

  The reference study provides new evidence that activation of PINK1/Park2-mediated mitophagy can relieve mitochondrial dysfunction and lipid accumulation in non-alcoholic fatty liver disease (NAFLD) models. These findings clarify the protective role of mitophagy in NAFLD pathology and highlight Park2 as a potential therapeutic target.

• Ginsenoside Rg1: Advanced Neuroprotection & Workflow Optimiz

  2026-05-17

  Ginsenoside Rg1, a triterpene saponin from Panax species, enables precise modulation of neuroimmune pathways for robust neuroprotection and inflammation studies. This guide details optimized experimental workflows, key protocol parameters, and troubleshooting strategies to maximize reproducibility and translational value using APExBIO’s high-purity Ginsenoside Rg1.

• (+)-Bicuculline: Technical Use as a GABAA Receptor Antagonis

  2026-05-16

  (+)-Bicuculline enables precise inhibition of GABAA receptors to dissect inhibitory synaptic transmission and modulate NMDA receptor signaling in neuroscience assays. It should only be used in controlled research environments with rigorous attention to solubility, storage, and workflow protocols. This compound is not suitable for diagnostic or clinical applications.

• LY2228820: Precision p38 MAP Kinase Inhibitor for Cellular A

  2026-05-15

  LY2228820 empowers researchers to dissect p38 MAPK signaling with unprecedented selectivity, supporting robust anti-inflammatory and cancer research. This guide delivers actionable workflows, protocol optimizations, and troubleshooting strategies to maximize reproducibility and scientific insight.

• EV-Transferred ACLY Drives Immunosuppressive Macrophage Diff

  2026-05-15

  This study uncovers how hepatocellular carcinoma (HCC) cells use extracellular vesicles to deliver ATP-citrate lyase (ACLY) into monocytes, inducing their differentiation into tumor-associated macrophages (TAMs) with potent immunosuppressive properties. These insights inform targeted strategies to modulate the tumor microenvironment and enhance immunotherapy in HCC.

• SOAT1 Inhibition Restores Lipophagy in PHMG-Induced Lung Fib

  2026-05-14

  This study identifies sterol O-acyltransferase 1 (SOAT1) as a key mediator of pulmonary fibrosis following polyhexamethylene guanidine (PHMG) exposure, linking SOAT1 upregulation to disrupted cholesterol handling and foam cell formation in alveolar macrophages. Targeting SOAT1 with avasimibe restored lipophagy and mitigated fibrosis, suggesting a promising therapeutic direction for PHMG-induced and possibly other lipid-driven fibrotic lung diseases.

• Gamithromycin: PK/PD-Driven Workflows for Respiratory Pathog

  2026-05-14

  Gamithromycin (ML-1709460) unlocks precision targeting of veterinary respiratory pathogens with data-backed dosing strategies and advanced PK/PD modeling. This guide translates breakthrough findings into actionable workflows, tackling both in vitro and in vivo models with real-world troubleshooting and optimization tips.

• Repurposing Novobiocin: In Vitro Activity Against SFTSV

  2026-05-13

  This article examines the recent in vitro evaluation of Novobiocin, an aminocoumarin antibiotic, and other FDA-approved drugs for antiviral activity against severe fever with thrombocytopenia syndrome virus (SFTSV). The study identifies Novobiocin as a promising antiviral compound, offering new avenues for antiviral and antibacterial resistance research.

• 40-Hz Light Flicker Regulates Retinal Microglia for Amyloid

  2026-05-13

  This study demonstrates that 40-Hz light flicker enhances retinal amyloid-β clearance in aged mice by upregulating MHC-II+ microglia activity. The findings highlight a non-invasive strategy for promoting metabolic waste removal in age-related retinal disorders and establish a mechanistic link between flicker stimulation and immune modulation.

• RG108 (A1913): Practical Insights for Epigenetic Modulation

  2026-05-12

  This article provides an evidence-based exploration of RG108 (SKU A1913), a DNA methyltransferase inhibitor, guiding biomedical researchers through real-world experimental challenges in cell-based assays. It distills validated workflows, protocol considerations, and vendor reliability, emphasizing reproducibility and practical advantages of using RG108 from APExBIO.

15142 records 1/1010 page Next 12345 下5页 Last page